| Literature DB >> 35162928 |
Frances F Graham1, Norah Finn2, Paul White3, Simon Hales1, Michael G Baker1.
Abstract
Legionnaires' disease (LD) (Legionella) is a common cause of community-acquired pneumonia (CAP) in those requiring hospitalization. Geographical variation in the importance of Legionella species as an aetiologic agent of CAP is poorly understood. We performed a systematic review and meta-analysis of population-based observational studies that reported the proportion of Legionella infection in patients with CAP (1 January 1990 to 31 May 2020). Using five electronic databases, articles were identified, appraised and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. The quality of the included studies was assessed using the Newcastle-Ottawa Scale. Univariate and multivariate meta-regression analyses were conducted using study design, WHO region, study quality and healthcare setting as the explanatory variables. We reviewed 2778 studies, of which 219 were included in the meta-analysis. The mean incidence of CAP was 46.7/100,000 population (95% CI: 46.6-46.8). The mean proportion of Legionella as the causative agent for CAP was 4.6% (95% CI: 4.4 to 4.7). Consequently, the mean Legionella incidence rate was 2.8/100,000 population (95% CI: 2.7-2.9). There was significant heterogeneity across all studies I2 = 99.27% (p < 0.0001). After outliers were removed, there was a decrease in the heterogeneity (I2 = 43.53%). Legionella contribution to CAP has a global distribution. Although the rates appear highest in high income countries in temperate regions, there are insufficient studies from low- and middle-income countries to draw conclusions about the rates in these regions. Nevertheless, this study provides an estimate of the mean incidence of Legionella infection in CAP, which could be used to estimate the regional and global burden of LD to support efforts to reduce the impact of this infection as well as to fill important knowledge gaps.Entities:
Keywords: Legionella; Legionnaires’ disease; community-acquired pneumonia; meta-analysis; systematic review
Mesh:
Year: 2022 PMID: 35162928 PMCID: PMC8835084 DOI: 10.3390/ijerph19031907
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Flowchart of systematic literature review and study selection for meta-analysis.
Figure 2Spatial distribution of CAP studies. Studies based on representative population sampling are considered as representative (yellow). Studies based on the records from multiple hospitals in different cities and studies based on records from laboratories that perform diagnostic testing for Legionella for patients throughout a region or country are considered as non-representative (green). Studies based in hospital settings whose patient populations are localized to a single city are considered localized (red points).
Summary of the contribution of Legionella spp. to CAP, CAP rates, and estimated Legionella rates globally and by the WHO region together with the confidence intervals.
| WHO Region | #Cases/#Participants | 95% CI | CAP Rate (per 100,000) | 95% CI | 95% CI | ||
|---|---|---|---|---|---|---|---|
| All Regions | 5723/125,764 | 4.6 | (4.4–4.7) | 46.7 | (46.6–46.8) | 2.8 | (2.7–2.9) |
| Africa | 48/2965 | 1.6 | (1.1–2.1) | 31.5 | (30.1–32.4) | 0.9 | (0.1–1.8) |
| Eastern Mediterranean | 248/2556 | 9.7 | (8.5–10.9) | 65.1 | (64.7–65.5) | 13.9 | (13.5–14.3) |
| Europe | 2529/56,537 | 4.5 | (4.3–4.6) | 62.9 | (62.8–63.0) | 2.4 | (2.3–2.5) |
| South-East Asian | 228/5267 | 4.3 | (3.7–4.9) | 132.7 | (132.3–133.1) | 3.4 | (2.9–3.8) |
| The Americas | 437/29,628 | 1.5 | (1.3–1.6) | 74.0 | (73.7–74.3) | 1.6 | (1.3–1.9) |
| Western Pacific | 1120/25,109 | 4.5 | (4.2–4.7) | 17.3 | (17.1–17.5) | 0.7 | (0.5–0.9) |
Figure 3Annual incidence of Legionella spp. infection (cases/100,000 population) among CAP patients (all ages) from 219 included studies for meta-analysis.
Summary of sensitivity analyses.
| Description | #Cases/#Participants | Pool Effect | 95% CI 1 | Model | ||
|---|---|---|---|---|---|---|
| All Regions | 5723/125,764 | 0.05 | (0.04–0.06) | 99.27% | <0.0001 | Random-effects |
| Africa | 48/2965 | 0.02 | (0.01–0.03) | 0.1092 | Random-effects | |
| (0.01–0.03) | 0.1092 | Fixed-effects | ||||
| Eastern Mediterranean | 248/2556 | 0.09 | (0.04–0.06) | <0.0001 | Random-effects | |
| Europe | 2529/56,537 | 0.06 | (0.04–0.06) | <0.0001 | Random-effects | |
| South-East Asian | 228/5267 | 0.07 | (0.04–0.06) | <0.0001 | Random-effects | |
| The Americas | 437/29,628 | 0.03 | (0.04–0.06) | <0.0001 | Random-effects | |
| Western Pacific | 1120/25,109 | 0.02 | (0.04–0.06) | <0.0001 | Random-effects |
1 CI, confidence interval.
Univariate and multivariate meta-regression for change in Legionella incidence involving several study characteristics.
| Univariate Analysis | Covariate | Number of Studies | β-Coefficient | 95% CI | Heterogeneity ( | Multivariate Analysis | β-Coefficient | 95% CI | Heterogeneity ( | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||
| Cross sectional | 7 | 0.0111 | −0.0535 to 0.0756 | 0.7368 | 99.15% | 0.0042 | −0.0579 to 0.0663 | 0.8949 | 98.40% | ||
| Prospective | 173 | − 0.0287 | −0.0765 to 0.0190 | 0.2380 | −0.0298 | −0.0771 to 0.0175 | 0.2167 | ||||
| Retrospective | 33 | − 0.0063 | −0.0571 to 0.0445 | 0.8082 | 0.0005 | −0.0492 to 0.0501 | 0.9855 | ||||
|
| |||||||||||
| Eastern Mediterranean | 15 | 0.0706 | 0.0213 to 0.1199 | 0.0050 | 98.83% | 0.0633 | 0.0099 to 0.1167 | 0.0201 | |||
| European | 117 | 0.0376 | −0.0049 to 0.0801 | 0.0830 | 0.0296 | −0.0168 to 0.0760 | 0.2109 | ||||
| South-East Asian | 12 | 0.0465 | −0.0043 to 0.0973 | 0.0730 | 0.0448 | −0.0119 to 0.1016 | 0.1217 | ||||
| The Americas | 31 | 0.0238 | −0.0214 to 0.0690 | 0.3023 | 0.0157 | −0.0331 to 0.0645 | 0.5287 | ||||
| Western Pacific | 38 | 0.0152 | −0.0292 to 0.0595 | 0.5024 | 0.0124 | −0.0358 to 0.0606 | 0.6139 | ||||
|
| |||||||||||
| Overall | 219 | −0.0001 | −0.0048 to 0.0046 | 0.9655 | 99.23% | −0.0005 | −0.0053 to 0.0043 | 0.8457 | |||
|
| |||||||||||
| Outpatients (with comorbidities) | 5 | −0.0020 | −0.0571 to 0.0532 | 0.9446 | 99.01% | −0.0024 | −0.0554 to 0.0505 | 0.9285 | |||
| Inpatients (no ICU) | 157 | 0.0167 | −0.0186 to 0.0520 | 0.3531 | 0.0107 | −0.0234 to 0.0449 | 0.5376 | ||||
| ICU patients only | 18 | 0.0397 | −0.0021 to 0.0532 | 0.0624 | 0.0352 | −0.0054 to 0.0759 | 0.0893 | ||||